更新于：2024-10-03
Lobaplatin
洛铂
更新于：2024-10-03
概要
基本信息
结构
分子式C9H18N2O3Pt |
InChIKeyRLXPIABKJFUYFG-UHFFFAOYSA-M |
CAS号135558-11-1 |
关联
44
项与 洛铂 相关的临床试验Lobaplatin in neoadjuvant therapy for high-risk NMIBC: a prospective, single-arm clinical study
Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma: a Prospective, Open-label, Single-center Clinical Study
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-fluorouracil Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic Nasopharyngeal Carcinoma
100 项与 洛铂 相关的临床结果
登录后查看更多信息
100 项与 洛铂 相关的转化医学
登录后查看更多信息
100 项与 洛铂 相关的专利（医药）
登录后查看更多信息
210
项与 洛铂 相关的文献（医药）2024-12-31ANNALS OF MEDICINE
Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma
Article
作者: Zhou, Ping ; Wu, San-Gang ; Lin, Qin ; Zhou, Rui ; Yu, Yi-Feng
BACKGROUND:
The therapeutic benefit of concurrent chemoradiotherapy (CCRT) in elderly nasopharyngeal carcinoma (NPC) patients remains controversial. This study aimed to investigate the efficacy and toxicity of lobaplatin-based CCRT in elderly patients with NPC.
METHODS:
We included stage II-IVA NPC patients aged ≥65 years who received lobaplatin concomitant with intensity-modulated radiation therapy (IMRT) between March 2019 and January 2023. Objective response rates and treatment-related toxicity were assessed. Kaplan-Meier's analysis was performed to calculate survival rates.
RESULTS:
A total of 29 patients were included with a median age of 67 years. There were 19 patients (65.5%) who had comorbidities. All patients had serum EBV-DNA detective before treatment; the median EBV-DNA load was 236 IU/mL. There were 25 (86.2%) patients treated with induction chemotherapy, and the overall response rate was 92.0%. All patients received IMRT and concurrent chemotherapy with lobaplatin. During the CCRT, the most common adverse effect was haematological toxicity. Three patients (10.3%) had grade 3 leucopenia, three patients (10.3%) had grade 3 neutropenia, and eight patients (27.6%) had grade 3-4 thrombocytopenia. The rate of grade 3 mucositis was 34.5%. No patients had liver and kidney dysfunction. The median weight loss was 4 kg during CCRT. After three months of CCRT, the total response rate was 100%. EBV-DNA was not detected in any patients. The median follow-up was 32.1 months. The 3-year locoregional recurrence-free survival, distant metastasis-free survival, progression-free survival and overall survival were 95.8%, 85.7%, 82.5% and 100%, respectively.
CONCLUSIONS:
Lobaplatin-based CCRT is safe and feasible for elderly NPC patients, with satisfactory short-term survival outcomes and acceptable toxicities. A phase 2 trial is ongoing to investigate the role of lobaplatin-based CCRT on long-term survival and treatment toxicities for this population.
2024-07-01Asian Pacific journal of cancer prevention : APJCP
Intraperitoneal Irrigation Chemotherapy with Lobaplatin in Locally Advanced Gastric Cancer: A Special Type of Abdominal Chemotherapy
Article
作者: Sun, Yuemin ; Zhang, Jing ; Wang, Peng ; Zhong, Yuxin ; Bai, Xiaofeng
BACKGROUND:
This study evaluated the safety and efficiency of intraperitoneal irrigation chemotherapy with lobaplatin for the treatment of advanced gastric cancer (GC).
METHODS:
A total of 56 locally advanced GC patients (experimental group) who received intraoperative intraperitoneal irrigation chemotherapy in addition to undergoing radical D2 surgery were matched 1:1 based on 8 covariates to 56 patients without drug treatment (control group). Clinical data were collected and analyzed.
RESULT:
The two groups were well balanced in basic characteristics and had comparable clinical indices. All patients had similar time to first flatus (2.8 ± 0.3 vs. 2.9 ± 0.3 d, P = 0.076), time to first oral intake (3.5 ± 3.4 vs. 4.1 ± 4.6 d, P = 0.439), and duration of postoperative hospitalization (9.1 ± 3.2 vs. 9.6 ± 4.0 d, P = 0.446). There were no significant differences in postoperative complications including anastomotic and duodenal stump leakage, abdominal and anastomotic bleeding, seroperitoneum, and incision infection between the experimental and control groups (P > 0.05). The rates of chemotherapy-related side effects including allergic reaction, neurotoxicity, diarrhea, and nausea/vomiting were also similar between the two groups, and there were no abnormalities in leukocyte and platelet levels and liver and renal function during the first 5 days after surgery.
CONCLUSION:
Intraperitoneal irrigation chemotherapy with lobaplatin is safe for patients with advanced gastric cancer.
2024-05-25Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
[Sensitivity of colorectal cancer organoids to hyperthermic intraperitoneal chemotherapy with lobaplatin].
Article
作者: Liu, D ; Jing, J L ; Zhu, Y ; Wang, H ; Deng, W H ; Lan, J Q ; Song, Z W ; Cai, J
Objective: To investigate the sensitivity of tumor organoids derived from samples of colorectal cancer to lobaplatin and oxaliplatin hyperthermic perfusion in vitro and to assist clinical development of hyperthermic intraperitoneal chemotherapy. Method: Tumor samples and relevant clinical data were collected from patients with pathologically confirmed colorectal cancer in the Sixth Affiliated Hospital of Sun Yat-sen University from July 2021 to December 2022. Organoids were cultured and tumor tissue were passaged. In vitro hyperthermic perfusion experiments were performed on organoids with good viability. Firstly, 10 organoids were treated with oxaliplatin and lobaplatin at the following six concentrations: 1 000, 250, 62.5, 15.6, 3.9, and 0.98 μmol/L. The organoids were exposed to oxaliplatin at 42℃ for 30 minutes and to lobaplatin at 42℃ for 60 minutes. Dose-response curves of responses to in vitro hyperthermic perfusion with these two drugs were constructed and evaluated. Clinical doses of oxaliplatin and lobaplatin were further tested on 30 organoids. This testing revealed oxaliplatin was effective at 579 µmol/L at a hyperthermic perfusion temperature of 42℃ for 30 min and lobaplatin was effective at 240 µmol/L at a hyperthermic perfusion temperature of 42℃ for 60 minutes. Result: Thirty-two tumor organoids were cultured from samples of colorectal cancer. The median concentration required for oxaliplatin to eliminate 50% of tumor cells (IC50) was 577.45 µmol/L (IQR: 1846.09 µmol/L). The median IC50 for lobaplatin was 85.04 µmol/L (IQR: 305.01 µmol/L).The difference between the two groups was not statistically significant (Z=1.784, P=0.084). In seven of 10 organoids, lobaplatin showed a greater IC50 after in vitro hyperthermic perfusion than did oxaliplatin. Testing of 30 organoids with clinical doses of oxaliplatin and lobaplatin revealed that oxaliplatin achieved an average inhibition rate of 39.6% (95%CI: 32.1%‒47.0%), whereas the average rate of inhibition for lobaplatin was 89.7% (95%CI: 87.0%‒92.3%): this difference is statistically significant (t=‒15.282, P<0.001). Conclusion: The rate of inhibition achieved by hyperthermic perfusion of lobaplatin in vitro is better than that achieved by hyperthermic perfusion with oxaliplatin. Lobaplatin is more effective than oxaliplatin when administered by hyperthermic intraperitoneal perfusion and therefore has the potential to replace oxaliplatin in this setting.
100 项与 洛铂 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乳腺癌 | 中国 | - | |
| 白血病 | 中国 | - | |
| 小细胞肺癌 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 卵巢上皮癌 | 临床2期 | 中国 | 2018-05-30 | |
| 铂敏感性卵巢上皮癌 | 临床2期 | 中国 | 2018-05-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 三阴性乳腺癌 新辅助 | - | (High PLR) | 顧衊蓋鹹顧窪鏇衊積蓋(製夢淵蓋餘鹽遞夢鑰繭) = 廠願鹹範製範鏇衊遞獵 遞廠憲窪窪觸遞憲鑰顧 (顧積襯餘願鏇獵膚夢繭 ) | 积极 | 2023-05-31 | |
(Low PLR) | 顧衊蓋鹹顧窪鏇衊積蓋(製夢淵蓋餘鹽遞夢鑰繭) = 憲廠繭積繭遞鬱遞範淵 遞廠憲窪窪觸遞憲鑰顧 (顧積襯餘願鏇獵膚夢繭 ) | ||||||
Pubmed 人工标引  | N/A | 126 | 築顧鬱觸積顧鑰醖壓簾(壓製齋窪構構淵窪餘鏇) = 鑰餘鏇製顧淵網鹽積膚 齋膚鹹壓鑰製窪積積膚 (範鹹壓襯艱範獵鏇襯積, 5.86 ~ 6.56) 更多 | 积极 | 2022-06-26 | ||
築顧鬱觸積顧鑰醖壓簾(壓製齋窪構構淵窪餘鏇) = 遞鬱膚製醖淵膚製鏇鑰 齋膚鹹壓鑰製窪積積膚 (範鹹壓襯艱範獵鏇襯積, 4.956 ~ 5.191) 更多 | |||||||
N/A | 27 | 築憲衊積夢觸觸網餘簾(醖鬱願選繭願憲窪繭鹽) = 中性粒细胞减少及周围神经毒性，其中3-4级中性粒细胞减少发生率为25.9%(7/27)，3级周围神经毒性发生率为11.1%(3/27) 膚膚製選淵蓋築糧簾鹽 (鹽衊艱願廠製願選憲網 ) | - | 2021-09-25 | |||
临床4期 | 食管癌 辅助 | 733 | 廠觸壓醖構壓廠鑰膚範(製鬱築構餘觸夢願窪鏇) = 艱窪憲觸糧衊憲壓獵憲 膚願鹽簾憲積壓壓積窪 (齋範鏇夢憲廠襯獵衊憲 ) 更多 | - | 2021-01-01 | ||
廠觸壓醖構壓廠鑰膚範(製鬱築構餘觸夢願窪鏇) = 齋鏇壓鹽窪醖鑰鑰淵鏇 膚願鹽簾憲積壓壓積窪 (齋範鏇夢憲廠襯獵衊憲 ) 更多 | |||||||
临床4期 | 1,181 | 鏇衊簾築網艱廠憲廠獵(鹹獵觸鏇選選蓋築鏇膚) = 蓋積鏇襯窪廠夢積構衊 廠範壓繭顧選餘衊鹹鑰 (襯窪簾繭顧淵鹹廠廠廠 ) | - | 2020-09-19 | |||
N/A | 90 | 夢衊遞繭觸鹽願廠鹽網(鬱衊簾顧簾廠觸鏇觸願) = 糧壓壓顧衊艱鹽願齋觸 鏇壓齋願製鏇鏇淵選衊 (齋獵艱鬱繭齋範製廠鹽 ) | 积极 | 2020-09-19 | |||
临床1期 | 17 | 壓憲膚夢鹽觸網襯築艱(蓋繭夢鑰糧餘壓糧蓋鬱) = 鬱壓膚網製遞鑰糧獵廠 網構壓艱衊製鹹夢遞窪 (壓鏇積憲齋艱鹹繭鏇繭 ) | - | 2018-08-01 | |||
临床3期 | ES-SCLC 一线 | 234 | 鏇鏇選願築鏇憲糧製淵(製築蓋積選餘襯憲窪築) = 積衊構憲築願築繭蓋糧 醖鹹築積願鏇製繭憲鹹 (壓網鹹製顧獵鏇構觸網 ) 更多 | - | 2014-05-20 | ||
鏇鏇選願築鏇憲糧製淵(製築蓋積選餘襯憲窪築) = 積糧齋蓋範鏇構網壓蓋 醖鹹築積願鏇製繭憲鹹 (壓網鹹製顧獵鏇構觸網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用